Insmed's shares recover as analysts highlight positive trial data

Insmed Inc's shares plunged after its experimental drug to treat a form of bacterial lung infection failed the main goal of a trial, but the stock clawed back much of its early losses after analysts said positive secondary data was more relevant. Insmed's shares were down 12 percent in afternoon trading, recovering from a 34 percent plunge in premarket trading. The company said the inhaled antibiotic, Arikayce, failed to reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections. But the sputum cultures of 11 of the 44 patients given the drug did not show bacteria, meeting the mid-stage trial's secondary goal of culture conversion, Insmed said.



via Health News Headlines - Yahoo News http://ift.tt/P1usIF